Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Bitcoin Well (V.BTCW) Reports Q1 2024 Financial Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(81)
•••
Post by GRAMPS1996on Jun 28, 2018 6:54pm
106 Views
Post# 28248063

21 NR SO FAR THIS YEAR

21 NR SO FAR THIS YEAR

Theralase Researchers Receive Government Grant

Filing Services Canada 11 hours ago

Theralase Strengthens Its Patent Portfolio with an Additional US Patent Covering Metal-Glycoprotein Complexes, Including Rutherrin(R) Based Photo Dynamic Therapy, in Immune Privileged Sites

Filing Services Canada 6 days ago

Theralase Cancer Therapy: In Search of Medicine’s Holy Grail

Jeff Nielson 7 days ago

Theralase(R) Demonstrates Significant Advantage in Treatment of Brain Tumours

Filing Services Canada June 11, 2018

Theralase Demonstrates 36 Months Stability of Lead Anti-Cancer Drug

Filing Services Canada June 6, 2018

Theralase Release 1Q2018 Financial Statements

Filing Services Canada May 30, 2018

Theralase Successfully Completes Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study

Filing Services Canada May 30, 2018

Theralase Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study

Filing Services Canada May 17, 2018

Theralase Announces Completion of Non-Brokered Private Placement of Units for Aggregate Gross Proceeds of Approximately $1.02 million

Filing Services Canada May 14, 2018

Theralase Announces Proposed Non-Brokered Private Placement of up to $1 Million

Filing Services Canada May 8, 2018

Theralase Increases Revenue 22% for 2017 Financial Statements

Filing Services Canada April 30, 2018

Theralase Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer (NMIBC) Clinical Study

Filing Services Canada April 16, 2018

Theralase Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer

Filing Services Canada March 27, 2018

Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells

Filing Services Canada March 15, 2018

Rutherrin(R) Technology Granted Allowance for Canadian Patent

Filing Services Canada March 7, 2018

Theralase Advances Anti-Cancer Technology in Destruction of Human Lung Cancer

Filing Services Canada March 5, 2018

Theralase Announces Settlement Agreement with Ontario Securities Commission

Filing Services Canada February 26, 2018

Theralase Anti-Cancer Technology Treats Sixth Patient for Bladder Cancer

Filing Services Canada February 9, 2018

Correcting and Replacing: Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

Filing Services Canada January 18, 2018

Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer

Filing Services Canada January 18, 2018

Theralase Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer

Filing Services Canada January 17, 2018

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities